tiprankstipranks
Trending News
More News >
LifeTech Scientific Corporation (HK:1302)
:1302
Hong Kong Market
Advertisement

LifeTech Scientific Corporation (1302) AI Stock Analysis

Compare
0 Followers

Top Page

HK:1302

LifeTech Scientific Corporation

(1302)

Select Model
Select Model
Select Model
Neutral 59 (OpenAI - 4o)
Rating:59Neutral
Price Target:
HK$2.00
▲(6.95% Upside)
The overall stock score is primarily influenced by strong financial performance, despite challenges in margins and cash flow stability. Technical analysis indicates bearish momentum, and the high P/E ratio suggests overvaluation, which negatively impacts the score. The absence of earnings call data and corporate events means these factors do not influence the score.

LifeTech Scientific Corporation (1302) vs. iShares MSCI Hong Kong ETF (EWH)

LifeTech Scientific Corporation Business Overview & Revenue Model

Company DescriptionLifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders. The company operates through Structural Heart Diseases Business, Peripheral Vascular Diseases Business, and Cardiac Pacing and Electrophysiology Business segments. Its products include LAmbre left atrial appendage closure systems, as well as CeraFlex, Cera, Heart, and Konara-MF VSD occluders; Ankura thoracic aortic aneurysm and abdominal aortic aneurysm stent graft systems; delivery systems, such as Fustar steerable and SteerEase introducers; Aegisy vena cava filters; Cera vascular plug systems; AcuMark sizing balloons; LawMax dilators; and SeQure snare systems, as well as pacemakers. The company is also involved in the biomedical research and development; manufacturing and trading of materials for hemp; staff training and internal personnel management business; information consulting for investors; and manufacturing and trading of medical devices, as well as technical, consulting, and technology services. It has operations in Mainland China, India, rest of Asia, Europe, South America, Africa, and internationally. LifeTech Scientific Corporation was founded in 1999 and is headquartered in Shenzhen, the People's Republic of China.
How the Company Makes MoneyLifeTech Scientific Corporation generates revenue through the sale of its medical devices, which are primarily used in interventional procedures to treat cardiovascular and neurovascular diseases. The company's revenue streams include direct product sales to hospitals and healthcare providers, as well as distribution agreements with partners in different regions. Additionally, LifeTech invests in research and development to innovate and expand its product offerings, which helps maintain a competitive edge in the market. Partnerships with international medical device companies and healthcare institutions also play a role in expanding its market presence and driving sales growth.

LifeTech Scientific Corporation Financial Statement Overview

Summary
LifeTech Scientific Corporation demonstrates strong revenue growth and maintains a healthy balance sheet with low leverage. However, declining margins and inconsistent cash flow generation pose challenges that could affect long-term sustainability. The company should address operational efficiencies and cash flow stability to enhance financial performance.
Income Statement
85
Very Positive
LifeTech Scientific Corporation shows strong revenue growth with a notable increase from 2019 to 2024. The gross profit margin remains robust, indicating efficient cost management and strong competitive positioning. However, a declining EBIT margin from 2023 to 2024 suggests increased operational costs, impacting profitability. The net profit margin has slightly decreased over the years, indicating some pressure on bottom-line growth.
Balance Sheet
78
Positive
The company's balance sheet is solid with a low debt-to-equity ratio, suggesting minimal leverage risk. The equity ratio is high, indicating strong capitalization and stability. However, the slight decrease in return on equity (ROE) suggests that profitability relative to shareholders' equity is under pressure, which can be a concern if it continues.
Cash Flow
65
Positive
Free cash flow has been inconsistent, with significant fluctuation over the years. The operating cash flow to net income ratio is not available for the latest period, making assessment difficult. The company must focus on stabilizing its free cash flow to support future investments and growth.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.30B1.27B1.10B925.33M642.30M
Gross Profit981.43M995.64M873.93M747.53M513.14M
EBITDA271.87M253.46M445.78M397.59M133.30M
Net Income222.39M263.24M325.34M292.47M216.09M
Balance Sheet
Total Assets4.90B4.70B3.69B3.18B2.95B
Cash, Cash Equivalents and Short-Term Investments1.18B1.18B833.79M1.48B1.14B
Total Debt4.98M9.30M9.67M15.67M185.98M
Total Liabilities1.42B1.37B769.05M653.61M596.06M
Stockholders Equity3.49B3.37B2.90B2.50B2.34B
Cash Flow
Free Cash Flow38.46M125.36M52.84M145.57M180.15M
Operating Cash Flow321.46M418.05M388.32M488.85M338.53M
Investing Cash Flow-517.53M-453.88M-458.47M-86.76M-341.63M
Financing Cash Flow-116.97M182.71M-215.20M-256.38M674.66M

LifeTech Scientific Corporation Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price1.87
Price Trends
50DMA
1.98
Negative
100DMA
1.85
Positive
200DMA
1.66
Positive
Market Momentum
MACD
-0.05
Positive
RSI
43.13
Neutral
STOCH
37.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1302, the sentiment is Neutral. The current price of 1.87 is below the 20-day moving average (MA) of 1.94, below the 50-day MA of 1.98, and above the 200-day MA of 1.66, indicating a neutral trend. The MACD of -0.05 indicates Positive momentum. The RSI at 43.13 is Neutral, neither overbought nor oversold. The STOCH value of 37.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1302.

LifeTech Scientific Corporation Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
7.83B35.3814.86%1.20%-5.18%-9.69%
59
Neutral
HK$8.08B105.061.98%3.42%-70.82%
59
Neutral
8.42B49.703.23%0.43%35.01%483.73%
51
Neutral
3.33B627.27-2.26%-4.38%0.00%
46
Neutral
25.31B-19.25-35.47%-1.04%60.66%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:1302
LifeTech Scientific Corporation
1.87
0.39
26.35%
MCRPF
MicroPort Scientific
1.85
1.16
168.12%
DE:818
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
2.74
1.45
112.40%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.38
0.71
105.97%
HK:2172
MicroPort NeuroTech Limited
13.17
5.53
72.38%
HK:6606
New Horizon Health Limited
14.14
0.00
0.00%

LifeTech Scientific Corporation Corporate Events

LifeTech Scientific Reports Mixed Interim Results Amidst Increased Expenses
Aug 29, 2025

LifeTech Scientific Corporation announced its interim results for the six months ending June 30, 2025, reporting a turnover of approximately RMB676.7 million, a 3.7% increase from the previous year. However, the company’s net profit, after accounting for non-recurring items, saw a significant decrease of 73.2% compared to the same period in 2024, primarily due to changes in financial asset gains and increased share-based payment expenses.

The most recent analyst rating on (HK:1302) stock is a Buy with a HK$2.50 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.

LifeTech’s Innovative Heart Device Gains Regulatory Approval
Aug 22, 2025

LifeTech Scientific Corporation has announced that its Congenital Heart Defect Occluder has been admitted into the National Medical Products Administration’s Special Examination and Approval Procedure for Innovative Medical Devices. This marks the company’s 16th product to achieve such recognition, highlighting its commitment to advancing medical technology for congenital heart diseases. The occluder, designed with a full nitinol metal structure, offers a bidirectional release mechanism, enhancing treatment options for patients with patent ductus arteriosus (PDA). This development is expected to expedite the product’s registration and launch, benefiting PDA patients and expanding LifeTech’s product portfolio.

The most recent analyst rating on (HK:1302) stock is a Buy with a HK$2.50 price target. To see the full list of analyst forecasts on LifeTech Scientific Corporation stock, see the HK:1302 Stock Forecast page.

LifeTech Scientific Announces Board Meeting to Review Interim Results
Aug 11, 2025

LifeTech Scientific Corporation has announced a board meeting scheduled for August 29, 2025, to discuss and approve the unaudited interim results for the first half of the year. The meeting will also consider the payment of an interim dividend and other business matters, potentially impacting the company’s financial strategy and shareholder returns.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 10, 2025